Conference Call with Indoco Remedies Management and Analysts on Q1FY23 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals firm Indoco Remedies announced Q1FY23 Result : During the first quarter of FY 2022-23, revenues of Indoco Remedies grew by 3.6% at Rs. 394.9 crores, as against Rs.381.2 crores, same quarter last year. EBIDTA to net sales for the quarter is 18.1% at Rs. 71.3 crores, compared to 22.8% at Rs. 86.8 crores, same quarter last year. For the quarter, the Profit After Tax to net sales is 9.7% at Rs. 38.5 crores, compared to 10.4% at Rs. 39.6 crores, same quarter last year. Commenting on the first quarter FY 2022-23 results, Aditi Panandikar, Managing Director, Indoco Remedies Ltd., said, “After a turbulent India Business performance of last year with highs & lows of Covid, I am happy to report that we have a steady performance in the Domestic Business and an excellent growth in the International Business” Result PDF
Conference Call with Indoco Remedies Management and Analysts on Q4FY22 Performance and Outlook. Listen to the full earnings transcript.